Shots:
- AviadoBio has entered into an exclusive option & license agreement with UgeneX Therapeutics to develop & commercialize UGX-202
- As per the deal, AviadoBio will receive an option to develop & commercialize UGX-202 for retinitis pigmentosa & other indications globally (excl. Greater China), while UgeneX will receive upfront payments, r&d milestones, & sales milestone payments of ~$413M, with net sales-based royalties
- UGX-202, an AAV gene therapy using visual optogenetics to deliver a light-sensitive protein to retinal cells via a single intravitreal administration, is being evaluated in retinitis pigmentosa & will enter clinical stage for a second undisclosed indication by year-end
Ref: AviadoBio | Image: AviadoBio & UgeneX Therapeutics | Press Release
Related News:- Zenas BioPharma Enters ~$2B Deal with InnoCare Pharma for Three Autoimmune Product Candidates
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
